Resection of symptomatic non–small cell lung cancer brain metastasis in the setting of multiple brain metastases

View More View Less
  • 1 Centre for Neurosurgery, Department of General Neurosurgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; and
  • | 2 Centre for Integrated Oncology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $515.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
Print or Print + Online

OBJECTIVE

Current guidelines primarily suggest resection of brain metastases (BMs) in patients with limited lesions. With a growing number of highly effective local and systemic treatment options, this view may be challenged. The purpose of this study was to evaluate the role of metastasectomy, disregarding BM count, in a comprehensive treatment setting.

METHODS

In this monocentric retrospective analysis, the authors included patients who underwent resection for at least 1 BM and collected demographic, clinical, and tumor-associated parameters. Prognostic factors for local control and overall survival (OS) were analyzed with the log-rank test and Cox proportional hazards analysis.

RESULTS

The authors analyzed 216 patients. One hundred twenty-nine (59.7%) patients were diagnosed with a single/solitary BM, whereas 64 (29.6%) patients had 2–3 BMs and the remaining 23 (10.6%) had more than 3 BMs. With resection of symptomatic BMs, a significant improvement in Karnofsky Performance Scale (KPS) was achieved (p < 0.001), thereby enabling adjuvant radiotherapy for 199 (92.1%) patients and systemic treatment for 119 (55.1%) patients. During follow-up, 83 (38.4%) patients experienced local recurrence. BM count did not significantly influence local control rates. By the time of analysis, 120 (55.6%) patients had died; the leading cause of death was systemic tumor progression. The mean (range) OS after surgery was 12.7 (0–88) months. In univariate analysis, the BM count did not influence OS (p = 0.844), but age < 65 years (p = 0.007), preoperative and postoperative KPS ≥ 70 (p = 0.002 and p = 0.005, respectively), systemic metastases other than BM (p = 0.004), adjuvant radiation therapy (p < 0.001), and adjuvant systemic treatment (p < 0.001) were prognostic factors. In regression analysis, the presence of extracranial metastases (HR 2.30, 95% CI 1.53–3.48, p < 0.001), adjuvant radiation therapy (HR 0.97, 95% CI 0.23–0.86, p = 0.016), and adjuvant systemic treatment (HR 0.37, 95% CI 0.25–0.55, p < 0.001) remained as independent factors for survival.

CONCLUSIONS

Surgery for symptomatic BM from non–small cell lung cancer may be indicated even for patients with multiple lesions in order to alleviate their neurological symptoms and to consequently facilitate further treatment.

ABBREVIATIONS

BM = brain metastasis; fRT = fractionated radiotherapy; KPS = Karnofsky Performance Scale; LC = local control; NSCLC = non–small cell lung cancer; OS = overall survival; SRS = stereotactic radiosurgery; WBRT = whole-brain radiation therapy.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $515.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
  • 1

    Lin X, DeAngelis LM. Treatment of Brain Metastases. J Clin Oncol. 2015;33(30):34753484.

  • 2

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):734.

  • 3

    Tabouret E, Chinot O, Metellus P, Tallet A, Viens P, Gonçalves A. Recent trends in epidemiology of brain metastases: an overview. Anticancer Res. 2012;32(11):46554662.

    • Search Google Scholar
    • Export Citation
  • 4

    Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494500.

    • Search Google Scholar
    • Export Citation
  • 5

    Vecht CJ, Haaxma-Reiche H, Noordijk EM, Padberg GW, Voormolen JH, Hoekstra FH, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?. Ann Neurol. 1993;33(6):583590.

    • Search Google Scholar
    • Export Citation
  • 6

    Bindal RK, Sawaya R, Leavens ME, Lee JJ. Surgical treatment of multiple brain metastases. J Neurosurg. 1993;79(2):210216.

  • 7

    Hazuka MB, Burleson WD, Stroud DN, Leonard CE, Lillehei KO, Kinzie JJ. Multiple brain metastases are associated with poor survival in patients treated with surgery and radiotherapy. J Clin Oncol. 1993;11(2):369373.

    • Search Google Scholar
    • Export Citation
  • 8

    Iwadate Y, Namba H, Yamaura A. Significance of surgical resection for the treatment of multiple brain metastases. Anticancer Res. 2000;20(1B):573577.

    • Search Google Scholar
    • Export Citation
  • 9

    Lee CH, Kim DG, Kim JW, Han JH, Kim YH, Park CK, et al. The role of surgical resection in the management of brain metastasis: a 17-year longitudinal study. Acta Neurochir (Wien). 2013;155(3):389397.

    • Search Google Scholar
    • Export Citation
  • 10

    Paek SH, Audu PB, Sperling MR, Cho J, Andrews DW. Reevaluation of surgery for the treatment of brain metastases: review of 208 patients with single or multiple brain metastases treated at one institution with modern neurosurgical techniques. Neurosurgery. 2005;56(5):10211034.

    • Search Google Scholar
    • Export Citation
  • 11

    Salvati M, Tropeano MP, Maiola V, Lavalle L, Brogna C, Colonnese C, et al. Multiple brain metastases: a surgical series and neurosurgical perspective. Neurol Sci. 2018;39(4):671677.

    • Search Google Scholar
    • Export Citation
  • 12

    Schackert G, Lindner C, Petschke S, Leimert M, Kirsch M. Retrospective study of 127 surgically treated patients with multiple brain metastases: indication, prognostic factors, and outcome. Acta Neurochir (Wien). 2013;155(3):379387.

    • Search Google Scholar
    • Export Citation
  • 13

    Ammirati M, Nahed BV, Andrews D, Chen CC, Olson JJ. Congress of Neurological Surgeons systematic review and evidence-based guidelines on treatment options for adults with multiple metastatic brain tumors. Neurosurgery. 2019;84(3):E180E182.

    • Search Google Scholar
    • Export Citation
  • 14

    Bachelot T, Romieu G, Campone M, Diéras V, Cropet C, Dalenc F, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14(1):6471.

    • Search Google Scholar
    • Export Citation
  • 15

    Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, et al. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017;18(7):863873.

    • Search Google Scholar
    • Export Citation
  • 16

    Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629640.

    • Search Google Scholar
    • Export Citation
  • 17

    Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829838.

    • Search Google Scholar
    • Export Citation
  • 18

    Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379(8):722730.

    • Search Google Scholar
    • Export Citation
  • 19

    Carapella CM, Gorgoglione N, Oppido PA. The role of surgical resection in patients with brain metastases. Curr Opin Oncol. 2018;30(6):390395.

    • Search Google Scholar
    • Export Citation
  • 20

    Jünger ST, Schödel P, Ruess D, Ruge M, Brand JS, Wittersheim M, et al. Timing of development of symptomatic brain metastases from non-small cell lung cancer: impact on symptoms, treatment, and survival in the era of molecular treatments. Cancers (Basel). 2020;12(12):3618.

    • Search Google Scholar
    • Export Citation
  • 21

    Proescholdt M, Jünger ST, Schödel P, Schebesch KM, Doenitz C, Pukrop T, et al. Brain metastases in elderly patients—the role of surgery in the context of systemic treatment. Brain Sci. 2021;11(1):123.

    • Search Google Scholar
    • Export Citation
  • 22

    Schödel P, Jünger ST, Wittersheim M, Reinhardt HC, Schmidt NO, Goldbrunner R, et al. Surgical resection of symptomatic brain metastases improves the clinical status and facilitates further treatment. Cancer Med. 2020;9(20):75037510.

    • Search Google Scholar
    • Export Citation
  • 23

    Davis FG, Dolecek TA, McCarthy BJ, Villano JL. Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data. Neuro Oncol. 2012;14(9):11711177.

    • Search Google Scholar
    • Export Citation
  • 24

    Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17(7):976983.

    • Search Google Scholar
    • Export Citation
  • 25

    Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295(21):24832491.

    • Search Google Scholar
    • Export Citation
  • 26

    Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29(2):134141.

    • Search Google Scholar
    • Export Citation
  • 27

    Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):10491060.

    • Search Google Scholar
    • Export Citation
  • 28

    Ayas AW, Grau S, Jablonska K, Ruess D, Ruge M, Marnitz S, et al. Postoperative local fractionated radiotherapy for resected single brain metastases. Strahlenther Onkol. 2018;194(12):11631170.

    • Search Google Scholar
    • Export Citation
  • 29

    Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014;15(4):387395.

    • Search Google Scholar
    • Export Citation
  • 30

    Huang Y, Chow KKH, Aredo JV, et al. Epidermal growth factor receptor mutation status confers survival benefit in patients with non-small-cell lung cancer undergoing surgical resection of brain metastases: a retrospective cohort study. World Neurosurg. 2019;125:e487e496.

    • Search Google Scholar
    • Export Citation
  • 31

    Johnson ML, Sima CS, Chaft J, Paik PK, Pao W, Kris MG, et al. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. Cancer. 2013;119(2):356362.

    • Search Google Scholar
    • Export Citation
  • 32

    Jünger ST, Pennig L, Schödel P, Goldbrunner R, Friker L, Kocher M, et al. The debatable benefit of gross-total resection of brain metastases in a comprehensive treatment setting. Cancers (Basel). 2021;13(6):1435.

    • Search Google Scholar
    • Export Citation
  • 33

    Lee CC, Soon YY, Tan CL, Koh WY, Leong CN, Tey JCS, Tham IWK. Discordance of epidermal growth factor receptor mutation between primary lung tumor and paired distant metastases in non-small cell lung cancer: a systematic review and meta-analysis. PLoS One. 2019;14(6):e0218414.

    • Search Google Scholar
    • Export Citation
  • 34

    Mansfield AS, Aubry MC, Moser JC, Harrington SM, Dronca RS, Park SS, Dong H. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol. 2016;27(10):19531958.

    • Search Google Scholar
    • Export Citation
  • 35

    Preusser M, Berghoff AS, Berger W, Ilhan-Mutlu A, Dinhof C, Widhalm G, et al. High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer. Lung Cancer. 2014;83(1):8389.

    • Search Google Scholar
    • Export Citation
  • 36

    Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883892.

    • Search Google Scholar
    • Export Citation
  • 37

    Stewart EL, Tan SZ, Liu G, Tsao MS. Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review. Transl Lung Cancer Res. 2015;4(1):6781.

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 204 204 138
Full Text Views 25 25 14
PDF Downloads 30 30 18
EPUB Downloads 0 0 0